140 related articles for article (PubMed ID: 22361120)
1. Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form.
Pattani A; McKay PF; Curran RM; McCaffrey J; Gupta PN; Lowry D; Kett VL; Shattock RJ; McCarthy HO; Malcolm RK
Vaccine; 2012 Apr; 30(17):2778-85. PubMed ID: 22361120
[TBL] [Abstract][Full Text] [Related]
2. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.
Akagi T; Kawamura M; Ueno M; Hiraishi K; Adachi M; Serizawa T; Akashi M; Baba M
J Med Virol; 2003 Feb; 69(2):163-72. PubMed ID: 12683403
[TBL] [Abstract][Full Text] [Related]
3. Systemic and mucosal immune responses in mice after rectal and vaginal immunization with HIV-DNA vaccine.
Hamajima K; Hoshino Y; Xin KQ; Hayashi F; Tadokoro K; Okuda K
Clin Immunol; 2002 Jan; 102(1):12-8. PubMed ID: 11781062
[TBL] [Abstract][Full Text] [Related]
4. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.
Matoba N; Geyer BC; Kilbourne J; Alfsen A; Bomsel M; Mor TS
Vaccine; 2006 Jun; 24(23):5047-55. PubMed ID: 16621185
[TBL] [Abstract][Full Text] [Related]
5. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
Staats HF; Nichols WG; Palker TJ
J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
[TBL] [Abstract][Full Text] [Related]
6. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges.
Bomsel M; Tudor D; Drillet AS; Alfsen A; Ganor Y; Roger MG; Mouz N; Amacker M; Chalifour A; Diomede L; Devillier G; Cong Z; Wei Q; Gao H; Qin C; Yang GB; Zurbriggen R; Lopalco L; Fleury S
Immunity; 2011 Feb; 34(2):269-80. PubMed ID: 21315623
[TBL] [Abstract][Full Text] [Related]
7. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques.
Koopman G; Bogers WM; van Gils M; Koornstra W; Barnett S; Morein B; Lehner T; Heeney JL
J Med Virol; 2007 May; 79(5):474-82. PubMed ID: 17385685
[TBL] [Abstract][Full Text] [Related]
9. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.
Zhang H; Huang Y; Fayad R; Spear GT; Qiao L
J Virol; 2004 Aug; 78(15):8342-8. PubMed ID: 15254206
[TBL] [Abstract][Full Text] [Related]
10. Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract.
Hervouet C; Luci C; Cuburu N; Cremel M; Bekri S; Vimeux L; Marañon C; Czerkinsky C; Hosmalin A; Anjuère F
Vaccine; 2010 Aug; 28(34):5582-90. PubMed ID: 20600505
[TBL] [Abstract][Full Text] [Related]
11. AIDS vaccine: Intranasal immunization using inactivated HIV-1-capturing core-corona type polymeric nanospheres.
Akagi T; Ueno M; Hiraishi K; Baba M; Akashi M
J Control Release; 2005 Dec; 109(1-3):49-61. PubMed ID: 16256237
[TBL] [Abstract][Full Text] [Related]
12. Potent cross-reactive immune response against the wild-type and drug-resistant forms of HIV reverse transcriptase after the chimeric gene immunization.
Starodubova E; Boberg A; Ivanov A; Latyshev O; Petrakova N; Kuzmenko Y; Litvina M; Chernousov A; Kochetkov S; Karpov V; Wahren B; Isaguliants MG
Vaccine; 2010 Feb; 28(8):1975-86. PubMed ID: 20188253
[TBL] [Abstract][Full Text] [Related]
13. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
Devito C; Zuber B; Schröder U; Benthin R; Okuda K; Broliden K; Wahren B; Hinkula J
J Immunol; 2004 Dec; 173(11):7078-89. PubMed ID: 15557206
[TBL] [Abstract][Full Text] [Related]
14. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
[TBL] [Abstract][Full Text] [Related]
15. Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses.
Kato H; Bukawa H; Hagiwara E; Xin KQ; Hamajima K; Kawamoto S; Sugiyama M; Sugiyama M; Noda E; Nishizaki M; Okuda K
Vaccine; 2000 Jan; 18(13):1151-60. PubMed ID: 10649615
[TBL] [Abstract][Full Text] [Related]
16. Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice.
Kawamura M; Wang X; Uto T; Sato K; Ueno M; Akagi T; Hiraishi K; Matsuyama T; Akashi M; Baba M
J Med Virol; 2005 May; 76(1):7-15. PubMed ID: 15778965
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
[TBL] [Abstract][Full Text] [Related]
18. [Characterization of the HIV-1 subunit vaccine containing the gp41 NHR domain of the HIV-1 CRF01_AE recombinant subtype in China].
Shao JP; Jiang SB; Liu SW
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Dec; 28(12):1250-3. PubMed ID: 23232514
[TBL] [Abstract][Full Text] [Related]
19. Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses.
McKay PF; Mann JF; Pattani A; Kett V; Aldon Y; King D; Malcolm RK; Shattock RJ
J Control Release; 2017 Mar; 249():74-83. PubMed ID: 28115243
[TBL] [Abstract][Full Text] [Related]
20. Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms.
Donnelly L; Curran RM; Tregoning JS; McKay PF; Cole T; Morrow RJ; Kett VL; Andrews GP; Woolfson AD; Malcolm RK; Shattock RJ
Vaccine; 2011 Jun; 29(27):4512-20. PubMed ID: 21514349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
